Dermata Therapeutics, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21
	10-Q	10-Q	10-Q	10-Q	10-K	S-1	10-Q	10-Q
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	0.9	1.1	1.1	1.2	1.4	0.9	0.5	1.6
General and administrative	0.9	1.1	1.1	1.2	1.4	0.9	0.5	1.6
Research and development	0.8	1.2	1.6	1.6	1.1	0.8	0.9	0.7
EBITDA [+]
Depreciation and amortization
EBIT [+]	-1.7	-2.3	-2.7	-2.8	-2.6	-1.7	-1.3	-2.3
EBIT growth	-36.6%	-18.2%	105.3%	23.2%	419.5%	217.1%	67.8%
Interest income, net [+]	0.0	0.0				0.0	0.0	0.0
Interest expense						0.0	0.0	0.0
Interest income	0.0	0.0
Pre-tax income	-1.7	-2.2	-2.7	-2.8	-2.6	-1.7	-1.3	-2.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-1.7	-2.2	-2.7	-2.8	-2.6	-4.3	-1.3	-2.3

Basic EPS [+]	($0.63)	($2.27)	($3.90)	($5.35)	($0.59)	($0.86)	($0.70)	($1.21)
Growth	-83.9%	-57.5%	457.5%	343.8%	186.1%	174.6%	62.8%
Diluted EPS [+]	($0.63)	($2.27)	($3.90)	($5.35)	($0.59)	($0.86)	($0.70)	($1.21)
Growth	-83.9%	-57.5%	457.5%	343.8%	186.1%	174.6%	62.8%

Shares outstanding (basic) [+]	2.7	1.0	0.7	0.5	4.3	5.0	1.9	1.9
Growth	286.6%	89.4%	-63.2%	-72.8%	125.1%	160.6%	-0.4%
Shares outstanding (diluted) [+]	2.7	1.0	0.7	0.5	4.3	5.0	1.9	1.9
Growth	286.6%	89.4%	-63.2%	-72.8%	125.1%	160.6%	-0.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.